Article
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Clinical pharmacology and therapeutics - 1 Oct 2012
Eechoute K, van der Veldt A A M, Oosting S, Kappers M H W, Wessels J A M, Gelderblom H, Guchelaar H-J, Reyners A K L, van Herpen C M L, Haanen J B, Mathijssen R H J, Boven E
Abstract excerpt
Hypertension is an important side effect of sunitinib treatment. In a retrospective study in 255 patients, single-nucleotide polymorphisms (SNPs) in vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor (VEGFR)-2, endothelin-1 (ET-1), and endothelium-derived nitric oxide synthase (eNOS) were multivariately tested against hypertension grades and changes in systolic blood...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.